Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Georgetown University researchers have reaffirmed the cyclin D1 protein as a target for a breast cancer treatment strategy having identified it as an inhibitor of the cancer fighting gene BRCA1.
Subscribe to our email newsletter
For about a decade, scientists have recognized that many cases of hereditary breast cancer result from a mutation of a specific gene called BRCA1, which, in its normal state, helps keep tumor formation in check. About five to 10% of breast cancer cases arise from these genetic miscues, about half of which are linked to the abnormal functioning of BRCA1.
But now scientists Georgetown University Medical Center have discovered that a protein called cyclin D1, grossly overproduced in about half of all cases of breast cancer, can also disrupt BRCA1’s normal role as a cancer inhibitor. They found that because cyclin D1 binds to the same estrogen receptor as does BRCA1, when the cell is flooded with cyclin D1, BRCA1 is unable to activate a pathway that stops cancer development.
The results reaffirm cyclin D1 as a candidate target for molecular therapeutic control of breast tumor development.